Impel Pharmaceuticals Statistics
Total Valuation
IMPLQ has a market cap or net worth of $356,235. The enterprise value is $110.41 million.
| Market Cap | 356,235 |
| Enterprise Value | 110.41M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
IMPLQ has 23.75 million shares outstanding. The number of shares has increased by 0.17% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 23.75M |
| Shares Change (YoY) | +0.17% |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.02 |
| Forward PS | 0.01 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19
| Current Ratio | 0.19 |
| Quick Ratio | 0.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -127.40% |
| Return on Capital (ROIC) | -312.73% |
| Revenue Per Employee | $131,169 |
| Profits Per Employee | -$464,244 |
| Employee Count | 160 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 1.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.90% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -98.90% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.46 |
| Relative Strength Index (RSI) | 49.63 |
| Average Volume (20 Days) | 16,192 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IMPLQ had revenue of $20.99 million and -$74.28 million in losses. Loss per share was -$3.12.
| Revenue | 20.99M |
| Gross Profit | 11.03M |
| Operating Income | -71.59M |
| Pretax Income | -74.28M |
| Net Income | -74.28M |
| EBITDA | -59.42M |
| EBIT | -61.90M |
| Loss Per Share | -$3.12 |
Balance Sheet
The company has $4.74 million in cash and $114.80 million in debt, giving a net cash position of -$110.06 million or -$4.63 per share.
| Cash & Cash Equivalents | 4.74M |
| Total Debt | 114.80M |
| Net Cash | -110.06M |
| Net Cash Per Share | -$4.63 |
| Equity (Book Value) | -91.91M |
| Book Value Per Share | -3.87 |
| Working Capital | -101.32M |
Cash Flow
In the last 12 months, operating cash flow was -$79.09 million and capital expenditures -$2.88 million, giving a free cash flow of -$81.98 million.
| Operating Cash Flow | -79.09M |
| Capital Expenditures | -2.88M |
| Free Cash Flow | -81.98M |
| FCF Per Share | -$3.45 |
Margins
Gross margin is 52.58%, with operating and profit margins of -341.13% and -353.93%.
| Gross Margin | 52.58% |
| Operating Margin | -341.13% |
| Pretax Margin | -353.93% |
| Profit Margin | -353.93% |
| EBITDA Margin | -283.14% |
| EBIT Margin | -294.96% |
| FCF Margin | -390.60% |
Dividends & Yields
IMPLQ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.17% |
| Shareholder Yield | -0.17% |
| Earnings Yield | -20,851.12% |
| FCF Yield | -23,011.77% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | 74.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IMPLQ has an Altman Z-Score of -23.55 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.55 |
| Piotroski F-Score | 3 |